United States Patent 8,241,649: Claims, Scope, Expiration, and Adapalene-Benzoyl Peroxide Patent Landscape

US Patent 8,241,649 protects a narrow aqueous gel formulation combining 0.1% adapalene, 2.5% to 5% dispersed benzoyl peroxide, and 3.5% to less than 4% of a specific acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80 gelling system. The patent also protects the same formulation when packaged in a container for once-daily acne treatment.

The patent is directed to formulation composition and packaged-product claims, not to adapalene or benzoyl peroxide as chemical entities. Its commercial relevance is linked to adapalene/benzoyl peroxide topical products, including Epiduo and potentially therapeutically equivalent generic products.

What does US Patent 8,241,649 cover?

US 8,241,649 covers a specific aqueous gel containing three required formulation components:

Required element	Claimed limitation
Retinoid	0.1% adapalene and/or a pharmaceutically acceptable salt
Antimicrobial/oxidizing agent	2.5% to 5% dispersed benzoyl peroxide
Gelling system	3.5% to less than 4% acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80
Dosage form	Physiologically acceptable aqueous gel
Use	Once-daily treatment of common acne
Measurement basis	Percentages by total composition weight

Claim 1 is a composition claim. Claim 2 is a product claim requiring a container holding the claimed aqueous gel. The patent identifies Galderma as the commercial patent holder or originating applicant associated with this adapalene/benzoyl peroxide formulation technology. The issued patent date was August 14, 2012. [1]

How should claim 1 be construed?

Claim 1 requires every listed formulation limitation. A competing product generally would need to satisfy all material elements for literal infringement.

Adapalene concentration

The claim requires 0.1% adapalene. A product containing 0.3% adapalene would not literally satisfy the 0.1% limitation, although separate patents or regulatory protections may apply to higher-strength products.

The phrase “and/or at least one pharmaceutically acceptable salt thereof” broadens the active-retinoid limitation beyond neutral adapalene. In practice, commercial adapalene products generally use adapalene itself rather than a salt form.

Benzoyl peroxide range

The claim covers benzoyl peroxide concentrations from 2.5% through 5%, assuming conventional interpretation of the endpoints. The claim requires the benzoyl peroxide to be dispersed in the aqueous gel.

A formulation containing less than 2.5% or more than 5% benzoyl peroxide would fall outside the literal numerical range. A formulation with 2.5%, 3%, 4%, or 5% benzoyl peroxide falls within the stated range if the other limitations are met.

Gelling-agent range

The most restrictive limitation is the gelling system concentration: 3.5% to less than 4% by total composition weight.

This creates a narrow claimed interval:

Concentration	Literal position under claim 1
3.49%	Outside the stated range
3.50%	Within the range
3.75%	Within the range
3.99%	Within the range
4.00%	Outside the stated “less than 4%” upper boundary

The relevant ingredient is not merely any acrylamide-based polymer. The claim identifies a combined gelling material consisting of acrylamide sodium acryloyldimethyltaurate copolymer, isohexadecane, and polysorbate 80. A formulation using a different polymer, a different emulsifier, or a different hydrocarbon carrier may avoid literal infringement, depending on the composition and claim construction.

What does claim 2 protect?

Claim 2 protects a packaged product containing the same formulation required by claim 1. It requires:

A container.
An aqueous gel inside the container.
0.1% adapalene or an acceptable salt.
2.5% to 5% dispersed benzoyl peroxide.
3.5% to less than 4% of the specified gelling system.
Intended once-daily acne treatment.

The product claim can be important in commercial enforcement because it reaches finished, packaged goods rather than only bulk formulation. A manufacturer, contract packager, distributor, or applicant marketing a containerized product could face a claim directed to the product itself if all limitations are present.

The claim does not appear to require a particular tube, pump, label, trade dress, package size, or dispensing mechanism. The container limitation is therefore broad in format but narrow in substance because the container must hold the claimed gel.

When does US Patent 8,241,649 lose exclusivity?

The patent’s base statutory term is tied to its earliest applicable nonprovisional priority date. The relevant priority history places the expected base expiration in December 2027. The precise enforceable expiration must be determined from the USPTO patent-term calculation, including any patent-term adjustment and terminal disclaimer information. [1][2]

Event	Date or status
Earliest reported priority period	December 2006
U.S. patent grant	August 14, 2012
Expected base patent-term end	December 2027
Patent-term adjustment	Must be checked in the USPTO record
Regulatory exclusivity	Separate from patent term
Orange Book relevance	Depends on listing and the approved product to which the patent is linked

Patent expiration does not eliminate other patents covering related products. A generic entrant may face separate patents directed to formulations, delivery systems, manufacturing processes, or higher-strength adapalene products.

What is the Orange Book status of the adapalene and benzoyl peroxide product?

The FDA Orange Book identifies patents and regulatory exclusivity associated with approved drug products. Epiduo, the fixed-dose adapalene/benzoyl peroxide gel, was approved by the FDA under NDA 022320. The product contains 0.1% adapalene and 2.5% benzoyl peroxide and is indicated for topical treatment of acne vulgaris. [3][4]

The Orange Book significance of US 8,241,649 depends on whether the patent is listed against the relevant NDA and whether its claims read on the approved product. Orange Book listing does not itself establish patent validity or infringement. It determines whether an ANDA applicant must address the listed patent through a Paragraph IV certification, a section viii statement, or another applicable certification pathway.

A listed patent can delay approval under the Hatch-Waxman framework if the NDA holder or patent owner brings timely infringement litigation after receiving a Paragraph IV notice. The statutory stay can last up to 30 months, subject to statutory exceptions and court action. [5]

What Paragraph IV challenges affect this patent?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. An ANDA applicant seeking approval for an adapalene/benzoyl peroxide gel could challenge US 8,241,649 if the patent is listed against the reference product and the applicant’s proposed formulation implicates the patent claims.

Potential Paragraph IV positions include:

The prior art disclosed an adapalene and benzoyl peroxide combination.
The claimed polymer system and concentration range were obvious.
The patent lacks adequate written description or enablement for the full claimed range.
The proposed generic does not contain the required gelling system.
The proposed product contains the gelling system outside the claimed concentration range.
The product is not packaged or labeled for the claimed once-daily acne treatment.
The patent is unenforceable because of inequitable conduct or another litigation defense.

The strongest formulation-specific defense would usually focus on the gelling system and its concentration. The active ingredients alone do not define the full scope of the claims.

How strong is the patent estate for Epiduo?

The patent estate has moderate formulation strength but limited breadth at the ingredient level.

Strengths

The claims require a commercially relevant fixed-dose combination.
The gelling-agent identity is specific.
The 3.5% to less than 4% range can capture a narrow but commercially selected formulation.
Claim 2 reaches packaged products.
The claims may be difficult to avoid if a generic replicates the reference formulation closely.

Weaknesses

Adapalene and benzoyl peroxide were individually known before the patent.
The active ingredients are not claimed broadly as chemical entities.
The benzoyl peroxide range is relatively broad and may be vulnerable to prior-art overlap.
The gelling-agent range is narrow and may invite an obviousness or anticipation challenge based on formulation optimization.
Small formulation changes may move a product outside the literal scope.
The once-daily treatment language may raise claim-construction questions concerning whether it is a binding limitation or primarily intended use.

Patent validity would depend heavily on the cited prior art, prosecution history, specification examples, and evidence regarding unexpected stability, tolerability, delivery, or performance advantages.

What formulations are protected by US 8,241,649?

The protected formulation must be an aqueous gel containing the specified ingredients within the stated ranges.

Formulation scenario	Likely claim position
0.1% adapalene, 2.5% BPO, 3.75% specified gelling system	Within claim scope if all other limitations are met
0.1% adapalene, 2.5% BPO, 4.0% gelling system	Outside literal claim 1 because the upper limit is less than 4%
0.3% adapalene, 2.5% BPO, 3.75% gelling system	Outside literal claim 1 due to adapalene concentration
0.1% adapalene, 1% BPO, 3.75% gelling system	Outside literal claim 1 due to BPO concentration
0.1% adapalene, 2.5% BPO, carbomer instead of the specified polymer blend	Likely outside literal claim 1
0.1% adapalene, 2.5% BPO, specified gelling system in an anhydrous cream	Outside literal claim 1 due to aqueous-gel limitation
Bulk gel with no container	Potentially within claim 1, but not claim 2
Packaged gel with all required components	Potentially within claims 1 and 2

The doctrine of equivalents could create risk for formulations near a numerical boundary, but prosecution history and the deliberate “less than 4%” language may restrict the ability to treat 4% as equivalent to a concentration below 4%.

How does the patent compare with adapalene and benzoyl peroxide prior-art patents?

The relevant landscape has several layers:

Patent layer	Subject matter	Relevance to US 8,241,649
Adapalene compound patents	Adapalene molecule and retinoid activity	Generally expired or separate from the formulation claims
Benzoyl peroxide patents	Benzoyl peroxide as an acne active	Generally old and not sufficient alone to establish infringement
Combination patents	Adapalene plus benzoyl peroxide	Directly relevant to fixed-dose acne products
Formulation patents	Aqueous gels, dispersion, stability, rheology	Most relevant to US 8,241,649
Product and packaging claims	Containerized formulation	Relevant to finished generic products
Higher-strength patents	0.3% adapalene and related formulations	More relevant to Epiduo Forte than standard Epiduo
Manufacturing patents	Mixing, dispersion, polymer hydration, scale-up	Can create separate process risk

The key competitive question is not whether a generic uses adapalene and benzoyl peroxide. It is whether the generic reproduces the claimed polymer system and concentration window.

What generic launch risks exist?

A generic manufacturer has four principal design options:

Replicate the formulation and challenge the patent under Paragraph IV.
Use a non-infringing formulation and pursue approval with a Paragraph III or other certification strategy, depending on listed patents.
Alter the gelling system or concentration outside the claimed range.
Wait for patent expiry while preparing an ANDA.

Design-around risk is strongest around the gelling system. A manufacturer could use a different rheology modifier, alter the polymer blend, or formulate outside the 3.5% to less than 4% range. Those changes may affect viscosity, suspension stability, spreadability, preservative performance, and bioequivalence.

A design-around product still must satisfy FDA requirements for pharmaceutical equivalence, product quality, bioequivalence, and labeling. A formulation that avoids patent infringement may require additional development work and may not be therapeutically or commercially identical to the reference product.

What litigation and settlement issues matter?

The primary litigation risk would arise if an ANDA applicant filed a Paragraph IV certification against a listed patent and the patent owner sued within the statutory period. Relevant litigation issues would include:

Whether the patent is properly listed against the reference product.
Whether the proposed generic contains the claimed polymer blend.
Whether the gelling-agent concentration is within the claimed range.
Whether the once-daily treatment limitation is satisfied by the proposed label.
Whether the patent is invalid over earlier acne formulations.
Whether prosecution amendments created estoppel against a doctrine-of-equivalents theory.
Whether a settlement permits a licensed or date-certain generic launch.

A settlement could provide a generic launch date before patent expiry, subject to antitrust review and the terms of the agreement. The patent record alone does not establish the existence or terms of a particular settlement agreement.

What is the commercial exposure?

Epiduo is a topical acne product, so revenue exposure is smaller than for high-cost specialty medicines but potentially significant because acne treatment has a large patient population and high prescription volume. Commercial exposure depends on:

Brand and generic prescription share.
Reimbursement and substitution.
Retail and mail-order distribution.
Physician preference for combination topical therapy.
Availability of over-the-counter benzoyl peroxide products.
Generic formulation economics.
Whether a generic can launch before patent expiry.
The presence of Epiduo Forte and other adapalene products in the same franchise.

US 8,241,649 is more important as a barrier to close formulation substitution than as a broad monopoly over adapalene/benzoyl peroxide therapy.

What geographic coverage does the patent provide?

US 8,241,649 provides rights only in the United States. It does not create rights in Canada, Europe, Japan, China, or other markets.

Related international applications may have produced corresponding national patents, but each jurisdiction has separate:

Claim scope.
Patent term.
Prosecution history.
Validity standards.
Orange Book or analogous regulatory listing rules.
Litigation and settlement record.

A global launch analysis therefore must review the relevant national family members rather than relying on the U.S. patent.

Key Takeaways

US 8,241,649 is a narrow formulation patent.
It requires 0.1% adapalene, 2.5% to 5% dispersed benzoyl peroxide, and 3.5% to less than 4% of a specified polymer/isohexadecane/polysorbate 80 gelling system.
Claim 1 covers the aqueous gel; claim 2 covers a container holding that gel.
The patent does not broadly monopolize adapalene, benzoyl peroxide, or all adapalene/benzoyl peroxide combinations.
The gelling-agent identity and concentration range are the principal infringement battlegrounds.
The expected base patent term ends in December 2027, subject to the official USPTO term calculation.
Generic applicants can challenge the patent through Paragraph IV or pursue a formulation design-around.
A generic product using a different gelling system or a concentration outside the claimed range may reduce infringement risk.
Orange Book status, prosecution history, patent-term adjustment, and litigation records control the final launch analysis.

FAQs

Does US 8,241,649 cover Epiduo Forte?

Not on the face of the supplied claims. Claim 1 requires 0.1% adapalene, while Epiduo Forte contains 0.3% adapalene. Epiduo Forte may be protected by separate patents or regulatory protections.

Can a generic use 2.5% benzoyl peroxide and avoid the patent?

No. The claim expressly includes 2.5% benzoyl peroxide. A generic using 2.5% benzoyl peroxide must avoid at least one other limitation, such as the specified gelling system or its concentration range, unless it successfully challenges the patent.

Is a 4% concentration of the gelling system covered?

Not literally under the stated claim. The claim covers 3.5% to less than 4%, making 4% an express boundary exclusion. Equivalence arguments would depend on the prosecution history and technical evidence.

Does the patent cover a cream instead of an aqueous gel?

No, not literally. The claims require a physiologically acceptable aqueous gel composition. A cream, ointment, lotion, or anhydrous formulation would need separate infringement analysis.

Can a company sell the same gel in a different container?

A different container may still infringe claim 2 because the claim does not require a particular container design. Changing the container alone would not avoid claim 1 and may not avoid claim 2 if the packaged composition remains within the claimed formulation.

References

United States Patent and Trademark Office. (2012). U.S. Patent No. 8,241,649, pharmaceutical composition comprising adapalene and benzoyl peroxide.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information.
U.S. Food and Drug Administration. (2008). Epiduo (adapalene and benzoyl peroxide) gel, 0.1%/2.5%: Prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j), Hatch-Waxman abbreviated new drug application provisions.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	01 16747	Dec 21, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1458369	⤷ Start Trial	CA 2008 00029	Denmark	⤷ Start Trial
European Patent Office	1458369	⤷ Start Trial	08C0024	France	⤷ Start Trial
European Patent Office	1458369	⤷ Start Trial	SPC/GB10/005	United Kingdom	⤷ Start Trial
European Patent Office	1458369	⤷ Start Trial	C01458369/01	Switzerland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,241,649

Summary for Patent: 8,241,649